← Catalyst calendarICU biotech catalysts & pipeline
SEASTAR MEDICAL HOLDING CORP · Data as of 2026-09-08
Upcoming catalysts
selective cytopheretic device — Topline data
Late 2026
Advance the SCD therapy for the adult AKI indication through completion of enrollment in the NEUTRALIZE-AKI pivotal trial around the end of 2026 and begin submission of relevant PMA modules to the FDA to facilitate the PMA review and approval process.
Source filingSCD therapy — NDA/BLA submission
Late 2027
Completion of enrollment is anticipated around year end or into the first quarter of 2027, which would enable a PMA application to the FDA near the end of 2027, pending a positive outcome of the trial.
Source filingExplore the free biotech catalyst calendar